User login
Key clinical point: Compared with regorafenib, raltitrexed plus S-1 (RS) prolonged overall survival without causing unmanageable adverse effects in patients with metastatic colorectal cancer (mCRC) who did not respond to previous standard treatments.
Major finding: Patients receiving RS vs. regorafenib had a significantly longer overall survival (13.3 vs. 10.0 months; P = .02). Adverse events were well tolerated in both the groups.
Study details: The findings are from a real-world, retrospective cohort study including 187 adult patients with mCRC who received RS or regorafenib after the failure of ≥2 standard treatments and were propensity score-matched to form 78 pairs.
Disclosures: This study was sponsored by the Sichuan Science and Technology Department Key Research and Development Project, among others. The authors declared no conflicts of interest.
Source: Zhou Y-W et al. Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study. Therap Adv Gastroenterol. 2022 (May 18). Doi: 10.1177/17562848221098246
Key clinical point: Compared with regorafenib, raltitrexed plus S-1 (RS) prolonged overall survival without causing unmanageable adverse effects in patients with metastatic colorectal cancer (mCRC) who did not respond to previous standard treatments.
Major finding: Patients receiving RS vs. regorafenib had a significantly longer overall survival (13.3 vs. 10.0 months; P = .02). Adverse events were well tolerated in both the groups.
Study details: The findings are from a real-world, retrospective cohort study including 187 adult patients with mCRC who received RS or regorafenib after the failure of ≥2 standard treatments and were propensity score-matched to form 78 pairs.
Disclosures: This study was sponsored by the Sichuan Science and Technology Department Key Research and Development Project, among others. The authors declared no conflicts of interest.
Source: Zhou Y-W et al. Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study. Therap Adv Gastroenterol. 2022 (May 18). Doi: 10.1177/17562848221098246
Key clinical point: Compared with regorafenib, raltitrexed plus S-1 (RS) prolonged overall survival without causing unmanageable adverse effects in patients with metastatic colorectal cancer (mCRC) who did not respond to previous standard treatments.
Major finding: Patients receiving RS vs. regorafenib had a significantly longer overall survival (13.3 vs. 10.0 months; P = .02). Adverse events were well tolerated in both the groups.
Study details: The findings are from a real-world, retrospective cohort study including 187 adult patients with mCRC who received RS or regorafenib after the failure of ≥2 standard treatments and were propensity score-matched to form 78 pairs.
Disclosures: This study was sponsored by the Sichuan Science and Technology Department Key Research and Development Project, among others. The authors declared no conflicts of interest.
Source: Zhou Y-W et al. Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study. Therap Adv Gastroenterol. 2022 (May 18). Doi: 10.1177/17562848221098246